{
  "cik": 1953926,
  "cik_padded": "0001953926",
  "entityName": "Zenas BioPharma, Inc.",
  "fiscal_years": [
    {
      "accn": "0001104659-26-027964",
      "filed": "2026-03-16",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 18000.0,
        "cash": 110641000.0,
        "eps_diluted": -8.44,
        "free_cash_flow": -172351000.0,
        "net_income": -377737000.0,
        "operating_cash_flow": -172333000.0,
        "operating_income": -383057000.0,
        "revenue": 10000000.0,
        "stockholders_equity": 242144000.0,
        "total_assets": 383640000.0,
        "total_liabilities": 141496000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.5843465045592705,
        "revenue_growth_yoy": 1.0,
        "roa_avg2y": -1.0024760883642425,
        "roa_period_end": -0.9846131790219999,
        "roe_avg2y": -1.362191265087396,
        "roe_period_end": -1.5599684485264966
      }
    },
    {
      "accn": "0001104659-26-027964",
      "filed": "2026-03-16",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 131000.0,
        "cash": 319742000.0,
        "eps_diluted": -11.89,
        "free_cash_flow": -119805000.0,
        "net_income": -156988000.0,
        "operating_cash_flow": -119674000.0,
        "operating_income": -163888000.0,
        "revenue": 5000000.0,
        "stockholders_equity": 312458000.0,
        "total_assets": 369968000.0,
        "total_liabilities": 57510000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "revenue_growth_yoy": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.1840567372254831,
        "revenue_growth_yoy": -0.9,
        "roa_avg2y": -0.7165980444963802,
        "roa_period_end": -0.42432859058080696,
        "roe_avg2y": -3.6198623424836,
        "roe_period_end": -0.5024291264745981
      }
    },
    {
      "accn": "0001104659-26-027964",
      "filed": "2026-03-16",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 17000.0,
        "cash": 56857000.0,
        "eps_diluted": -24.25,
        "free_cash_flow": -30546000.0,
        "net_income": -37124000.0,
        "operating_cash_flow": -30529000.0,
        "operating_income": -37147000.0,
        "revenue": 50000000.0,
        "stockholders_equity": -225721000.0,
        "total_assets": 68180000.0,
        "total_liabilities": 43815000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "net_margin": "ratio",
        "operating_margin": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "net_margin": -0.74248,
        "operating_margin": -0.7429400000000002,
        "roa_period_end": -0.5444998533294221,
        "roe_avg2y": 0.17762381969679933
      }
    },
    {
      "accn": "0001558370-25-002631",
      "filed": "2025-03-11",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -192286000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001104659-26-027964",
    "filed": "2026-03-16",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001953926.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001953926.json"
  },
  "ticker": "ZBIO"
}